Clinical stage life science in-vitro diagnostics company focused on accurately detecting debilitating diseases sooner with a lead assay for early detection of pancreatic cancer supported by clinical published data. Open $3M Seed round ($1.5M soft circled with 2 VC co-leads) funds opening of clinical lab, CLIA regulatory milestone, commercial launch in 2023, and scales additional assays on their proprietary ultrasensitive chemistry platform.